AstraZeneca (LON:AZN) Earns Buy Rating from Jefferies Financial Group

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a note issued to investors on Tuesday,Digital Look reports. They presently have a £180 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 32.68% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Citigroup increased their price objective on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and set a £115 target price on shares of AstraZeneca in a research note on Tuesday, June 2nd. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of £153.33.

Get AstraZeneca alerts:

Check Out Our Latest Report on AstraZeneca

AstraZeneca Price Performance

AZN stock opened at £135.66 on Tuesday. The stock has a market capitalization of £210.39 billion, a price-to-earnings ratio of 20.43, a PEG ratio of 0.86 and a beta of 0.21. The firm’s 50-day moving average price is £141.96 and its two-hundred day moving average price is £141.42. AstraZeneca has a 12-month low of £101.03 and a 12-month high of £157.32. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Further Reading

• Five stocks we like better than AstraZeneca
• AirJoule Technologies: A Cool Shot at a Multibagger
• Walmart’s No. 2 Ranking Hides a Digital Transformation Story
• Campbell’s Soup Stock: Deep Value and a 7% Dividend Yield
• 3 Stocks With Fresh Catalysts to Watch Before the July 4

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.